NCT05672355 2026-03-05
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Recruiting
Clinical Trials
34 trialsNCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT04830046 2025-11-26
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
Completed
NCT05655546 2025-08-08
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
Phase NA Terminated
NCT06070961 2025-06-29
FIL_FollVax22
Fondazione Italiana Linfomi - ETS
Recruiting
NCT05386355 2025-03-11
MoVeUP
IDeA States Pediatric Clinical Trials Network
Phase NA Completed
NCT04466098 2025-01-29
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04575064 2024-10-09
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Klinikum Bremen-Mitte, gGmbH
Phase 2/3 Withdrawn
NCT06482281 2024-07-03
COVID-19 and Childhood Cancer
Karolinska Institutet
Active not recruiting
NCT05422937 2024-05-22
SPLaT-19
Keele University
Completed
NCT04666025 2024-04-08
SARS-CoV-2 Donor-Recipient Immunity Transfer
City of Hope Medical Center
Completed
NCT05465876 2024-04-04
PACE-CLL
Sunnybrook Health Sciences Centre
Phase 2 Withdrawn
NCT05125562 2024-02-13
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Direct Biologics, LLC
Phase 2 Withdrawn
NCT04358406 2023-11-28
Rhu-pGSN for Severe Covid-19 Pneumonia
BioAegis Therapeutics Inc.
Phase 2 Completed
NCT05803395 2023-11-28
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT05303376 2023-09-13
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
Immune Biosolutions Inc
Phase 1/2 Completed
NCT05855395 2023-07-12
The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19
Huashan Hospital
Phase NA Unknown
NCT05827341 2023-06-18
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Sun Yat-sen University
Completed
NCT05393999 2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2 Withdrawn
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT04422470 2023-01-26
CHRONOS19
National Research Center for Hematology, Russia
Completed
NCT05371275 2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2 Withdrawn
NCT04352556 2022-09-23
COVID19-hematological Malignancies: the Italian Hematology Alliance
Ospedale di Circolo - Fondazione Macchi
Unknown
NCT04330261 2022-05-17
PERN-COVID-19
University of Calgary
Completed
NCT04453384 2022-03-25
POLYCOR
Nantes University Hospital
Phase 2 Completed
NCT04760184 2022-02-08
AutoCOVID-19
Uppsala University
Completed
NCT04803227 2022-01-04
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Histogen
Phase 1 Terminated
NCT04641806 2021-08-19
LYMPHO-Cov-2
Versailles Hospital
Withdrawn
NCT04982042 2021-08-04
COVID19REHAB
Centro Universitário de Anapolis
Phase NA Unknown
NCT04873414 2021-06-02
PlaSenTer
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
Phase 2/3 Unknown
NCT04477655 2021-04-13
PRO-CARF
Hospital Civil de Guadalajara
Phase NA Completed
NCT04745416 2021-02-09
Clinical Characteristics of Patients With Leukemia and COVID-19
Hospital General de Mexico
Completed
NCT04564040 2020-12-29
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
Phase 1 Completed
NCT04544878 2020-09-10
CLOVIS
Bicetre Hospital
Unknown